|
1
|
Greenlee RT, Murray T, Bolden S and Wingo
PA: Cancer statistics, 2000. CA Cancer J Clin. 50:7–33. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weir HK, Thun MJ, Hankey BF, Ries LA, Howe
HL, Wingo PA, Jemal A, Ward E, Anderson RN and Edwards BK: Annual
report to the nation on the status of cancer, 1975–2000, featuring
the uses of surveillance data for cancer prevention and control. J
Natl Cancer Inst. 95:1276–1299. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zlotnik A: Chemokines and cancer. Int J
Cancer. 119:2026–2029. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Premack BA and Schall TJ: Chemokine
receptors: gateways to inflammation and infection. Nat Med.
2:1174–1178. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bagglioni M: Chemokines and leukocyte
traffic. Nature. 392:565–568. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bleul CC, Schultze JL and Spinger TA: B
lymphocyte chemotaxis regulated in association with microanatomic
localization, differentiation state and B cell receptor engagement.
J Exp Med. 187:753–762. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schimanski CC, Schwald S, Simiantonaki N,
Javasinghe C, et al: Effect of chemokine receptors CXCR4 and CCR7
on the metastatic behavior of human colorectal cancer. Clin Cancer
Res. 11:1743–1750. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hao L, Zhang C, Wang L, Luo Y, et al:
Recombination of CXCR4, VEGF and MMP-9 predicting lymph node
metastasis in human breast cancer. Cancer Lett. 253:34–42. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shanmugam MK, Manu KA, Ong TH,
Ramachandran L, Surana R, Bist P, Lim LH, Kumar AP, Hui KM and
Sethi G: Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid
leads to suppression of metastasis in transgenic adenocarcinoma of
mouse prostate model. Int J Cancer. 129:1552–1563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
D'Alterio C, Barbieri A, Portella L, Palma
G, Polimeno M, Riccio A, Ieranò C, Franco R, Scognamiglio G, Bryce
J, et al: Inhibition of stromal CXCR4 impairs development of lung
metastases. Cancer Immunol Immunother. 61:1713–1720. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liang Z, Yoon Y, Votaw J, Goodman MM,
Williams L and Shim H: Silencing of CXCR4 blocks breast cancer
metastasis. Cancer Res. 65:967–971. 2005.PubMed/NCBI
|
|
12
|
Smith MC, Luker KE, Garbow JR, Prior JL,
Jackson E, Piwnica-Worms D and Luker GD: CXCR4 regulates growth of
both primary and metastatic breast cancer. Cancer Res.
64:8604–8612. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Phillips RJ, Burdick MD, Lutz M, Belperio
JA, Keane MP and Strieter RM: The stromal derived
factor-1/CXCL12-CXC chemokine receptor 4 biological axis in
non-small cell lung cancer metastases. Am J Respir Crit Care Med.
167:1676–1686. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun XS, Wei L, Chen Q and Terek RM:
CXCR4/SDF1 mediate hypoxia induced chondrosarcoma cell invasion
through ERK signaling and increased MMP1 expression. Mol Cancer.
9:172010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pan J, Mestas J, Burdick MD, Phillips RJ,
Thomas GV, Reckamp K, Belperio JA and Strieter RM: Stromal derived
factor-I (SDF-I/CXCL12) and CXCR4 in renal cell carcinoma
metastasis. Mol Cancer. 5:562006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kollmar O, Rupertus K, Scheuer C, Junker
B, et al: Stromal cell-derived factor-1 promotes cell migration and
tumor growth of colorectal metastasis. Neoplasia. 9:862–870. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mori T, Doi R, Koizumi M, Toyoda E, et al:
CXCR4 antagonist inhibits stromal cell-derived factor-1-induced
migration and invasion of human pancreatic cancer. Mol Cancer Ther.
3:29–37. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu L, Cecil J, Peng SB, Schrementi J, et
al: Identification and expression of novel isoforms of human
stromal cell-derived factor 1. Gene. 374:174–179. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Janowski M: Functional diversity of SDF-1
splicing variants. Cell Adh Migr. 3:243–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lombardi L, Tavano F, Morelli F, Latiano
TP, Di Sebastiano P and Maiello E: Chemokine receptor CXCR4: Role
in gastrointestinal cancer. Crit Rev Oncol Hematol. 88:696–705.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chada S, Ramesh R and Mhashilkar AM:
Cytokine- and chemokine-based gene therapy for cancer. Curr Opin
Mol Ther. 5:463–474. 2003.PubMed/NCBI
|
|
22
|
Dimberg J, Hugander A, Löfgren S and
Wagsater D: Polymorphism and circulating levels of the chemokine
CXCL12 in colorectal cancer patients. Int J Mol Med. 19:11–15.
2007.PubMed/NCBI
|
|
23
|
Allami RH: Influence of the chemokine
CXCL12 on the progression and the signalling in colorectal cancer.
PhD dissertation. Der Johannes Gutenberg-Universität. (ArchiMed,
Mainz). 2013.
|
|
24
|
Manetti M, Liakouli V, Fatini C, Cipriani
P, Bonino C, Vettori S, Guiducci S, Montecucco C, Abbate R,
Valentini G, Matucci-Cerinic M, Giacomelli R and Ibba-Manneschi L:
Association between a stromal cell derived factor1 (SDF-1/cxcl12)
gene polymorphism and microvascular disease in systemic sclerosis.
Ann Rheum Dis. 68:408–411. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu W, Zhu E, Wang R, Wang L and Liu T:
CXCL12 G801A polymorphism is associated with an increased risk of
benign salivary gland tumors in the Chinese population. Med Oncol.
29:677–681. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu L, Cecil J, Peng SB, Schrementi J,
Kovacevic S, Paul D, Su EW and Wang J: Identification and
expression of novel isoforms of human stromal cell-derived factor
1. Gene. 374:174–179. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Winkler C, Modi W, Smith MW, Nelson GW, Wu
X, Carrington M, Dean M, Honjo T, Tashiro K, Yabe D, Buchbinder S,
Vittinghoff E, Goedert JJ, O'Brien TR, Jacobson LP, Detels R,
Donfield S, Willoughby A, Gomperts E, Vlahov D, Phair J and O'Brien
SJ: Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine
gene variant variant. ALIVE Study, Hemophilia Growth and
Development Study (HGDS), Multicenter AIDS Cohort Study (MACS),
Multicenter Hemophilia Cohort Study (MHCS). San Francisco City
Cohort (SFCC) Science. 279:389–393. 1998.
|
|
28
|
Razmkhah M, Doroudchi M, Ghayumi SM,
Erfani N and Ghaderi A: Stromal cell-derived factor-1 (SDF-1) gene
and susceptibility of Iranian patients with lung cancer. Lung
Cancer. 49:311–315. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Razmkhah M, Talei AR, Doroudchi M,
Khalili-Azad T and Ghaderi A: Stromal cell-derived factor-1 (SDF-1)
alleles and susceptibility to breast carcinoma. Cancer Lett.
225:261–266. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dommange F, Cartron G, Espanel C, Gallay
N, Domenech J, Benboubker L, Ohresser M, Colombat P, Binet C,
Watier H and Herault O: GOELAMS Study Group: CXCL12 polymorphism
and malignant cell dissemination/tissue infiltration in acute
myeloid leukemia. Faseb J. 20:1913–1915. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hirata H, Hinoda Y, Kikuno N, Kawamoto K,
Dahiya AV, Suehiro Y, Tanaka Y and Dahiya R: CXCL12 G801A
polymorphism is a risk factor for sporadic prostate cancer
susceptibility. Clin Cancer Res. 13:5056–5062. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
de Oliveira KB, Oda JM, Voltarelli JC,
Nasser TF, Ono MA, Fujita TC, Matsuo T and Watanabe MA: CXCL12
rs1801157 polymorphism in patients with breast cancer, Hodgkin's
lymphoma and non-Hodgkin's lymphoma. J Clin Lab Anal. 23:387–393.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Teng YH, Liu TH, Tseng HC, Chung TT, Yeh
CM, Li YC, Ou YH, Lin LY, Tsai HT and Yang SF: Contribution of
genetic polymorphisms of stromal cell-derived factor-1 and its
receptor, CXCR4, to the susceptibility and clinicopathologic
development of oral cancer. Head Neck. 31:1282–1288. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vairaktaris E, Vylliotis A, Spyridonodou
S, Derka S, Vassiliou S, Nkenke E, Yapijakis C, Serefoglou Z,
Neukam FW and Patsouris E: A DNA polymorphism of stromal-derived
factor-1 is associated with advanced stages of oral cancer.
Anticancer Res. 28:271–275. 2008.PubMed/NCBI
|
|
35
|
Zhu K, Jiang B, Hu R, Yang Y, Miao M, Li Y
and Liu Z: The CXCL12 G801A polymorphism is associated with cancer
risk: A meta-analysis. PLoS One. 9:e1089532014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hidalgo-Pascual M, Galan JJ, Chaves-Conde
M, Ramírez-Armengol JA, Moreno C, Calvo E, Pelaez P, Crespo C, Ruiz
A and Royo JL: Analysis of CXCL12 3′UTR G>A polymorphism in
colorectal cancer. Oncol Rep. 18:1583–1587. 2007.PubMed/NCBI
|
|
37
|
Chang SC, Lin PC, Yang SH, Wang HS, Li AF
and Lin JK: SDF-1alpha G801A polymorphism predicts lymph node
metastasis in stage T3 colorectal cancer. Ann Surg Oncol.
16:2323–2330. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gong H, Tan M, Wang Y, Shen B, Liu Z,
Zhang F, Liu Y, Qiu J, Bao E and Fan Y: The CXCL12 G801A
polymorphism and cancer risk: evidence from 17 case-control
studies. Gene. 509:228–231. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Altenburg JD, Broxmeyer HE, Jin Q, Cooper
S, Basu S and Alkhatib G: A naturally occurring splice variant of
CXCL12/stromal cell-derived factor 1 is a potent human
immunodeficiency virus type 1 inhibitor with weak chemotaxis and
cell survival activities. J Virol. 81:8140–8148. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Janowski M: Functional diversity of SDF-1
splicing variants. Cell Adh Migr. 3:243–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sun X, Cheng G, Hao M, Zheng J, Zhou X,
Zhang J, Taichman RS, Pienta KJ and Wang J: CXCL12/CXCR4/CXCR7
chemokine axis and cancer progression. Cancer Metastasis Rev.
29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Colobran R, Pujol-Borrell R, Armengol MP
and Juan M: The chemokine network II. On how polymorphisms and
alternative splicing increase the number of molecular species and
configure intricate patterns of disease susceptibility. Clin Exp
Immunol. 150:1–12. 2007. View Article : Google Scholar : PubMed/NCBI
|
